AtlasClear Holdings Signs Letter of Intent to Acquire an Institutional Digital Asset Business and Advances Acquisition of Dawson James Securities AtlasClear's platform across traditional securities and institutional digital asset markets while adding established, revenue-generating operating businesses. The parties have agreed to keep the Target's identity confidential until execution of a definitive agreement. Based on 2025 year-end results, the Target generated approximately $9.2 million in revenue and $3.5 million in EBITDA, and Dawson James generated revenue of approximately $26.2 million and EBITDA of just over $3.2 million - a combined addition of approximately $35.4 million in revenue and approximately $6.7 million in EBITDA. Based on unaudited revenue through June 2026 provided by the Companies, the two businesses have a combined 2026 revenue run rate of over $56 Million.

BURU (NUBURU) — HARD AVOID

Four cents a share, delisted from NYSE American, and the only people pumping this online have a documented 3.7% win rate. Let's not dress it up.

Nuburu makes high-brightness blue lasers for welding and EV battery production — a real technology they've somehow converted into negative revenue. The TTM revenue figure is literally below zero because refunds exceed sales. They've been listed since 2020 and the share count has been reverse-split, re-diluted, reverse-split again, and re-diluted harder. The stock sits at $0.04 today, 98.8% below its 52-week high of $3.26. A 98.8% decline in a year is not a dip. That is a body.

On July 17, 2026, NYSE American formally started delisting proceedings because BURU was trading below $0.10 — the exchange's hard floor. The company is appealing. The same day they got delisted, they closed a $38 million public offering at $0.1555 per share, adding 117 million direct shares plus 127 million pre-funded warrants to a 249 million pre-offering share base. In roughly 45 days (circa September 1), Series B Preferred from that offering starts converting into up to 205 million more shares. Add it all up and the fully diluted share count is around 700 million — nearly tripling the pre-offering count from a single financing. Roughly half the gross proceeds went to pay down existing debt rather than build anything. Burn rate is $9.6 million per quarter, which buys about eight months of runway if they don't have to deploy capital for the acquisition.

The Tekne deal is the entire bull story: Nuburu signed in May 2026 to acquire 70% of Tekne S.p.A., an Italian NATO-accredited defense electronics firm with counter-drone and laser-dazzler systems. They ran laser dazzler tests on July 7 with "encouraging" results against two UAV platforms — genuinely interesting. But the deal cannot close until the Italian government completes its mandatory national-security review. That notification was filed June 5. Standard review is 45 days, which expired around July 20. It is now July 22 and Rome has said nothing. The Italian government can extend that clock or impose conditions with no obligation to hurry. The market has already priced in the uncertainty: the stock dropped 87% from its 60-day swing high of $0.32 to $0.04 after those encouraging tests. The crowd voted and it voted by selling.

The insiders have not bought a single share with their own cash in two years. The only "buying" on the filings is a director receiving shares when a creditor converted debt into equity at a discount — dilution wearing a buy label, not conviction. Both co-CEOs collect $600,000 in annual base salary plus 100% bonuses plus special awards, including a $330,000 bonus for "leading the Tekne acquisition work" while the stock cratered. The people closest to this engine are richly compensated and completely un-invested.

The retail buzz is artificial: the overwhelming majority of recent posts across penny stock forums come from a single account with a track record of winning less than 4% of the time. No independent crowd convergence. No multi-engine signal. Manufactured noise from a terrible manufacturer.

Zero near-term dated catalysts beyond the Italian approval, which has no timeline. No earnings date. No analyst coverage.

VERDICT: HARD AVOID. Counter-drone laser defense is a legitimate theme and the underlying technology is real. That does not excuse: active delisting proceedings, 700 million fully diluted shares, near-zero revenue, sub-nine-month runway, an unresolved foreign regulatory binary, and zero insider cash in the stock. This is a lottery ticket that the house is also trying to repossess. Pass.

Beam global is in my opinion is very exciting.

What they do:

Their primary flagship is their arc charging station. The arc is a standalone charging platform that does not require grid access, does not require permitting, and can be transported easily. They have contracts with a number of municipal govt providing these (city of long Beach, LAX, NYC).

They have a massive cataloged of patents, the one I am most excited for is thr Beamwell, which is a charger, but also is a probable desalinization. It is cheap, mobile and effective. This is important because they recently signed a partnership with Group UAE, which has recently seen their desalination infrastructure attackted.

They have also expanded into battery production from a company they purchased (allcell) and have received 500k in orders last week alone. Their batteries have patented thermal shielding technology as servicing underwater power storage.

Lastly, they have positioned themselves to be an all-in-one mobile disaster recovery solution, they have a number of patents here as well. This all plays well with escalating geo political tension, global warming and most govts move towards green energy. I encourage you to look over their product brochure.

Financials:

They have been burning cashing building out across the USA, europe and thr middle east. They have absobed AllCell, DOO Kralijevo, and Telcom. They also got shut out of govt contracts that their revenue was highly reliant on when Trump came to office. Since then they have successfully pivoted to the private and international market.

They have 0 debt and 100 million dollar credit line. The bankruptcy risk of the number is low on a penny stock. Also given the track record and performance of management I see this as quite an opportunity. After several years of negative growth they are posting 170% up over Q1.

They have an earnings report coming next month. I see this easily in thr 3-5 dollar range in the next 12 months.

They are currently trading around 1.10 down from a high pf over 70. However, this is not a penny stock and its valuation was the victim of circumstance.

What's up everyone,

AI gets the hype. Mining gets the data. The real story might be what happens when the two finally start talking to each other.

When people talk about artificial intelligence, the conversation usually goes toward chatbots, coding tools, and image generators.

A sector that gets much less attention is mining.

Modern mining operations produce huge amounts of data from drilling programs, geological surveys, equipment sensors, production systems, and environmental monitoring. The challenge is turning all that information into better decisions.

AI tools are already being explored for tasks like finding drilling targets, improving geological models, planning mine operations, monitoring equipment performance, improving worker safety, and reducing unnecessary exploration costs.

As mining companies collect more data and operations become more automated, software could become a much bigger part of how mines are discovered, built, and managed.

That's why I've been looking at exploration companies that are advancing mineral projects while also adopting new technology.

A few names I'm following:

• Kodiak Copper ($KDK) - Continuing its expanded drill campaign at MPD, where ongoing exploration is creating a growing dataset that can support geological modeling and future resource work.
• American Eagle Gold ($AE) - Running more than 50,000 metres of drilling at NAK, producing a large amount of geological information that can be analyzed with modern modeling tools.
• NRED ($NRED / $NREDF) - Advancing the Wilmac copper-gold project while developing the MetalCore AI platform for geological analysis and exploring EyeX computer vision technology for mining operations.
• Faraday Copper ($FDY) - Moving the Copper Creek project forward through technical studies, engineering work, and resource modeling as the company evaluates development options.
• Kingfisher Metals ($KFR) - Expanding its Golden Triangle exploration portfolio after Barrick's strategic investment, while applying modern exploration methods across a large land package.

The AI story is usually told through the companies building software and data centers. There is another side of the equation: the industries that provide the raw materials and infrastructure needed for the next technology cycle.

Mining has always been a data-heavy business. The companies that combine strong mineral projects with better ways to analyze and use that data could have an advantage as the industry becomes more technology-driven.

Better algorithms won't drill a hole. But they might tell you exactly where to put the first one.

This is something that bugged me for months. Every morning there's a sub-$5 name up 120%+ or something, on nothing, retail piles in, it collapses, and maybe months later there's an investigation. If manipulation is illegal, how is the stock allowed to trade the whole time it's happening?

The answer I landed on is this. Securities law doesn't ban a stock from moving violently. It bans the conduct used to manipulate it, such as, coordinated trading, undisclosed paid promo, lying to investors. But a 150% move, a tiny float, a reverse split, an insider selling, none of those are illegal by themselves. They're just red flags. The actual crime is hidden in the connections (who controlled the shares, who paid the promoter, who coordinated), and proving that takes bank records and messages, not a chart.

So by the time regulators can act, the round trip from $1 to $8 to $1 is already done. Enforcement ends up being a cleanup crew, not a barrier. Retail doesn't lose money when the case is announced but during the quiet investigation before it.

Curious what this sub thinks: should a stock get auto-halted when it rips 150% with no filing? Or would that just wreck legit small caps?

Drill results matter, but they only tell part of the story. Long before new discoveries show up in a resource estimate or financial model, management is already making decisions that shape where the business is headed.

That's why I spend as much time watching capital allocation, strategic partnerships and hiring as I do reading assay results. Those decisions often reveal what a company believes will create value five or ten years from now.

A few examples I've been following:

-Kingfisher Metals ($KFR) Recently secured a strategic investment from Barrick, providing both capital and validation as it continues advancing its Golden Triangle exploration portfolio.

-Hercules Metals ($BIG) Strengthened its balance sheet with a C$31.5 million financing following the Leviathan discovery, giving the company flexibility to continue aggressive exploration.

-NRED ($NRED / $NREDF) While advancing the Wilmac copper-gold project, the company has continued investing in MetalCore AI, expanded its advisory board with technology and commercialization expertise, and is pursuing AI applications that could complement its exploration business.

-Faraday Copper ($FDY) Completed a C$100 million financing backed by BHP and Lundin Mining while expanding its land position through the San Manuel acquisition, reinforcing its long-term development strategy.

-Kodiak Copper ($KDK) Chose to expand the 2026 MPD drill campaign to 16,500 metres with a second rig, signaling confidence in the scale and potential of the broader porphyry system.

Every company above is taking a different path, but they all have one thing in common: management is making decisions based on where they believe the opportunity will be years from now, not just next quarter. Those strategic moves rarely receive as much attention as drill results, but over time they often become some of the biggest drivers of long-term value creation.

CYCU is a cybersecurity company.

A victim of short selling and spoofing. They have a pending lawsuit against a large number of market makers and claim to have hard evidence to support their claims.

Everybody wants to find 5x to 10x return stocks. Here's a sleeper. Yesterday at $0.27 ($3M MC) and today ran to $0.44 so far and came back down to $.30. So, the word is getting out. I entered a comment on a YouTuber's penny-stock video page yesterday with some details about CYCU--asking him to make a video on CYCU. That video (on another stock) shows 2.5k views as of now, so maybe hundreds read my comment.

CYCU has a NASDAQ delisting notice, and they elected not to do a reverse split (had shareholder authority for a 1:7). The CEO and board felt they would be potentially shorted back down to under $1. They have asked NASDAQ for a hearing to get a short extension since they can no longer get 180-day extensions.

Latest acquisition has much higher profit margins and his 2026 revenue projection is $30M. That's right, $30M! And today started out with a $3.3M MC. Have cut debt about in half to around $4M and the new acquisition has margins as high as 65% to 70% (maybe double compared to their pre-existing business). The CEO predicts profitability by end of 2026 to Q1 2027.

Here's the 23-minute CEO (Kevin Kelly) interview published July 14: https://youtu.be/Bn45YsWdybU

My view is, I ultimately don't care if they have go to the OTC. I hope enough people watch the above video and choose to invest and keep it on the NASDAQ and get them over $1 for 10 consecutive days soon. But either way, there are so many companies on the OTC market that are doing very well -- for example, different business, but has anyone seen HGRAF (pre-revenue and over $1B valuation). If they have to move to OTC they can always relist on NASDAQ. It will have nothing to do with holding them back from reaching their 2026 revenue target. It will become a value story by end of the year.

I'm invested at $0.307. I'm holding this one for the 10x return (and potentially beyond). Not making the same mistake as when I bought DVLT at $.41, which ultimately hit $4, but I cashed out for only a double (I'll take it though!).

In my opinion, the stock should be well over $1 now. 5x (or $1.50) by end of 2026 to Q1 2027 is very realistic if annual revenue is anywhere close to $25M to $30M by end of 2026. Based on their projections at that point, meaning stability, profitability, and growth outlook given, then a gap up to 1x revenue (or $3) would make sense.

BIGGEST LOSERS :

Why are these stocks dropping so much?

Most of today's biggest losers have one or more of these characteristics:

• Low-float penny stocks that can move 30–80% in a single day.
• Share dilution or public offerings, increasing the number of shares outstanding.
• Nasdaq compliance or delisting concerns, especially for stocks trading below $1.
• Profit-taking after large rallies in previous sessions.
• Company-specific news such as disappointing earnings, financing announcements, or operational concerns.

Title: Coherus BioSciences' Aggressive Hiring Spree: Financial Desperation or Pipeline Confidence?

How is it possible for a company that the market treats as practically bankrupt to aggressively expand its commercial sales network? To the average investor looking at Coherus BioSciences (NASDAQ: CHRS), the math simply does not seem to add up. The stock has been trading at severely depressed levels, the company recently sold off its main cash-cow biosimilars, and it currently relies on just a single approved innovative drug, LOQTORZI. On paper, building a massive sales force under these financial pressures looks highly counterintuitive, if not outright reckless.

But this raises a critical question: is Coherus really a distressed company making a final, desperate gamble, or is there something much bigger happening behind the scenes?

Could it be that management is looking far beyond their single approved drug? It is highly probable that corporate insiders possess strong, positive data regarding their broader immuno-oncology pipeline. You do not build a commercial network just to sell one product; you build it because you are laying the groundwork for a massive multi-drug portfolio. With promising mid-stage candidates like Casdozokitug and Tagmokitug moving forward, this hiring surge strongly suggests that management knows something the public market doesn't yet see. Far from preparing for failure, Coherus might be quietly setting the stage to launch a powerful, multi-asset oncology powerhouse the moment their clinical data goes live.

The setup in one paragraph

A debt free company with over 60% of its market cap in cash, growing, inflecting to profitability, buying back stock while it's depressed, run by respiratory operators with M&A in their history, holding a free option on a $500M market, in an industry where every peer already got acquired. Priced at 0.18x sales against comps at 1.5x to 5.8x.
Early and wrong look identical on the tape. I've been early for a while. August 6 is the first checkpoint where the market gets a number it has to price.
Long 60,000 shares. Not advice. Do your own work

🚀 Biggest Winners

CleanTech Vanadium just outlined the permitting timeline for its Campbell-Crotser fluorspar project in Kentucky’s Illinois-Kentucky Fluorspar District.

They’re aiming to submit the main mine + processing plant permits by the end of November 2026. State approval is expected in the first half of 2027.

They’re also talking offtake deals and expect the first binding agreement by November 2026, with potential first product deliveries in 2028.

Acid-spar is critical for semiconductors, batteries, and nuclear fuel, and the Defense Logistics Agency has been looking to stockpile it.

Anyone following the fluorspar side of CTV or the Kentucky projects?

MJNA stock
Recent Business Highlights
Strategic Alliance: In early 2026, MJNA partnered with AXIM Biotechnologies to co-develop applications utilizing a patent for water-soluble cannabinoids. [1]
Operational Shift: Recent leadership transitions have prioritized structural profitability and global logistics expansion across their core HempMeds and Kannaway brands. [1, 2]
Market Status: Because it trades sub-penny on the OTC Markets, it exhibits extremely high volatility and limited liquidity compared to major stock exchanges. [1, 2]

​You guys want to know when a micro cap is actually mispriced, you look at what the big money is doing. Everyone is ignoring QYOU media right now because the daily volume on the TSXV is dead at like 9,300 shares a day. It is sitting around 28.5 cents CAD right now.

​But I just pulled the latest corporate updates and filings. Brand Capital International, which is the investment arm of the biggest media conglomerate in India, just agreed to put 2 million USD into QYOU. They even have an option to drop another 6 million in later. You can read the official release on it right here: https://www2.newsfilecorp.com/release/87231/Update-to-Brand-Capital-International-Investment-in-QYOU-Media

​Here is the crazy part. They agreed to a price of 32 cents CAD per share.

​Think about that for a second. Institutional money is locking in millions at 32 cents, and you can literally buy the stock on the open market right now for cheaper than the billionaires are paying. That creates a massive psychological floor.

​They also just booked Advertising Week New York to show off the influencer campaigns they are running for Paramount's biggest movies like Mission Impossible and A Quiet Place. The business just posted 32m in record revenue, and the parent market cap is only 15.8m. The free float is extremely tight at 46.7m shares. And if anyone is wondering how they funded their Chatterbox subsidiary IPO, they did another 2m raise earlier which you can verify here: https://www.prnewswire.com/news-releases/qyou-media-subsidiary-chatterbox-technologies-files-for-sme-ipo-in-india-302383045.html

​The volume is dead because the retail market is asleep. It is a quiet setup with the math right out in the open.

Join the wolf pack!

​Disclaimer: Not financial advice, just sharing the raw data. Micro caps are dangerous, so do your own digging. I hold shares.

GameSquare ha recentemente venduto 1.209 ETH e detiene circa 14.300 ETH al 14 luglio 2026. La priorità data al riacquisto di azioni riflette la convinzione del management che le azioni ordinarie di GameSquare offrano un interessante potenziale di rendimento alla luce del momentum positivo registrato sulla piattaforma dell'azienda.

Summary: OTC-listed Victory Marine Holdings Corp. (VMHG), operating through subsidiary Dunn & Groux Beverage Holdings (DGBH), put out a corporate update on 7/22/26. Breaking down what's confirmed vs. still pending per the release.

What's confirmed:

• GUTSI™ Fulvic & Humic Mineral Drops and Prebiotic Mineral Soda are now listed for sale on Amazon.com (can verify by searching the brand there).
• Company relaunched its DTC site, GetGUTSI.co, with expanded product/brand presentation and QR-enabled access to the portfolio.
• Second commercial production run of GUTSI™ Functional Mineral Hydration (500mL/1L PET formats) is scheduled to begin the week of 7/27/26. This follows an initial commercial hydration production run.
• GUTSI™ Functional Mineral Hydration is one of four platforms in the portfolio, alongside Prebiotic Mineral Soda, Fulvic & Humic Mineral Drops, and functional gummies.

What's pending/not final:

• Board authorized preparation of filings for a corporate name change (to Dunn & Groux Beverage Holdings, Inc.) and a corresponding trading-symbol change. Securities counsel has begun preparing submissions for Nevada corporate action and FINRA review. The release states this remains subject to completion of required filings, regulatory review, and applicable approvals.
• Q2 2026 financial statements and the related OTC Markets Quarterly Disclosure are currently being reviewed/completed by L&L CPAs, ahead of legal review and submission.
• Management is in the "final stage" of selecting a PCAOB-registered accounting firm to begin historical audits required to pursue full SEC reporting status.

Near-term priorities listed in the release:

• Submit Nevada/FINRA corporate-action materials
• Publish Q2 2026 financials and OTC Markets Quarterly Disclosure
• Finalize PCAOB auditor engagement and begin audit process
• Complete the second PET production run
• Expand Amazon/GetGUTSI.co consumer engagement
• Continue national retail, distribution, and production initiatives

Sol-Gel (SLGL) is an Israeli dermatology company whose value now rests almost entirely on one thing: a Phase 3 trial of SGT-610 (patidegib gel) for Gorlin syndrome, a rare genetic disorder that causes patients to develop large numbers of basal cell carcinomas.

Topline results are guided for Q4 2026. Alongside that, it holds a licensing book (Sun Pharma, Beimei, Searchlight, Mayne, Viatris and others) paying upfronts, milestones and royalties on two already-approved topical products, Twyneo and Epsolay, which it no longer sells directly.

A second pipeline asset, SGT-210 for Darier disease, failed its Phase 1b proof-of-concept in December 2025.

The balance sheet

• Cash & marketable securities ~$52.8m, up from ~$24.0m at Dec 31 2025, after a March 2026 offering raised $33.1m gross.
• No debt. Only quantified scheduled obligation outside leases is a $1.5m payment due Dec 2026 (Ajinomoto, tied to potential SGT-610 API manufacturing).
• Management guides cash to last into Q1 2028 (~7-8 quarters), comfortably past the Q4 2026 readout. (A raw cash-over-loss sum implies more, but management's shorter guidance reflects an expected spend ramp as the trial completes.
• The FY2025 20-F (filed March 19 2026) carried an explicit auditor going-concern paragraph, cash at Dec 31 2025 was judged insufficient for 12 months. The March raise materially addressed the liquidity condition behind that warning, days later.
• Revenue was $0.1m in Q1 2026 vs $1.0m a year earlier (a one-off Searchlight milestone didn't recur). FY2025 revenue of ~$19.4m was itself dominated by one-offs (a $16m Mayne US rights sale, milestones), so the business isn't predictably self-funding, those receipts are irregular.

At today's price, cash-adjusted enterprise value is roughly $240m, almost all of which is a bet on the one Q4 2026 trial, not the licensing tail.

The bull case if the trial reads out positive

• Gorlin syndrome has no therapy specifically approved to prevent new basal cell carcinomas; a positive confirmatory Phase 3 (113 randomized across 41 sites) carries real regulatory weight and re-rates the asset.
• Management estimates SGT-610 peak annual sales 'in excess of $600m' if approved (this is a company claim) and doubled from a $300m estimate two years ago
• A May 2026 Notice of Allowance, if the patent issues and is maintained, is expected to provide method-of-use protection through 2044.
• An HF-BCC expansion management says could roughly double the commercial opportunity — still preparatory, no funded trial design or timeline.

The bear case

• Concentration. After SGT-210 failed, there's no disclosed late-stage backup; the company is running very small low-cost feasibility studies rather than a new large trial. One real shot on goal.
• The Q4 2026 timeline already slipped once, from original 'end of 2025' guidance.
• The going-concern-then-raise sequence happened ~4 months ago and the business can't self-fund, so whether March was the last raise before readout is unknowable. An F-3 shelf remains open.
• Warrant overhang: 456k warrants (Armistice + Arkin, $58.50 strike) are in the money at today's price ~14% of the pre-raise share count in potential dilution.

Insider buying

Opaleye Management has made repeated open-market purchases from late 2025 through July 2026 (~7 months), with no sales in the Form 4s reviewed: roughly $2.78m across Dec 29-31 2025 near $42, then continued adds in May and July in the mid-$60s to ~$74.

Separately, a ~$2.86m purchase on March 24 2026 came at exactly $72, the offering price, so that one appears to be participation in the raise rather than an open-market buy.

Buying at $42 and again in the $70s across a large move reads as conviction. Caveat worth stating: this is a 10% institutional holder, not an officer or director — a specialist fund's conviction signal, not an operator with inside operational knowledge.

Bottom line

Binary setup with a Q4 2026 date. Cash comfortably covers the readout, which removes the near-term liquidity gun-to-the-head a lot of these names carry, but ~$240m of enterprise value is a wager on one trial.

A negative result leaves limited disclosed development value (though not nothing: cash, milestone/royalty economics, and modest SGT-210 optionality remain).

A positive one re-rates a drug with potential protection to 2044 and an HF-BCC expansion on top.

The one thing tilting bull-side; a major 10% holder has kept buying through the scare, and put fresh money into the raise itself.

Not financial advice. Do your own DD.

Sources used: getfactd.io/report/us/SLGL

I tried to post on WSB but as of this afternoon, we're about $800,000 short of the $500 mil rule.

$EVGO doesn't need to dilute when they have a US GOV DOE loan...

There's an imminent turnaround from this ATL and I feel it in me bones.

$EVGO just breached its all-time low at $1.60 🎉🎉🎉, leaving a ~35% short float (10+ days to cover) trapped in a classic overleveraged setup.

​Key Bull Drivers:

-Overblown Dilution Fears: Shorts bet on dilution, but EVgo tapped less than $20M of its $200M ATM since it opened in 2022. Why would they use it now?...expansion is funded by a $750M DOE loan.

-​EV Sales Bottomed: US EV sales bounced +15% QoQ in Q2 as market share held firm. Charger throughput keeps compounding.

-Path to #2 DC Network: Operating 5,200+ fast-charging stalls, EVgo is capturing the non-Tesla infrastructure expansion (GM/Pilot builds).

-I just bought my first EV last month with all this Iran BS. I needed a new car anyways so now I get to save money on not buying gas and oil changes (other maintenance). And it's really fun to drive.

​Trading at ~0.8x sales despite $110M Q1 revenue, $EVGO is completely mispriced at all-time lows.

--->The Play: Long shares or LEAPS before they panic-cover. Going half port tomorrow at market open. Get it while it's cold.

VisionWave Holdings (Nasdaq: $VWAV) has been filing IP at a steady clip. In the last week they announced two provisional patents:

GhostSight (July 17)
Hybrid passive radar / RF sensing architecture. It uses ambient RF signals plus their own cooperative illuminators. Receivers stay receive-only while AI fuses multi-band data for detection, tracking, and classification (including small drones and low-altitude threats). Aimed at counter-UAS, base protection, and infrastructure security.

SkyWeave (July 14)
AI-orchestrated high-frequency communication system designed for satellite-denied or infrastructure-denied environments. Uses AI for propagation analysis, intelligent listening, path prediction, and automated link management so operators (or autonomous systems) can maintain long-range comms without satellites or cellular networks.

These sit on top of the company’s broader platform work: the VARAN autonomous ground vehicle and drone systems shown at Eurosatory, the pending 51% acquisition of Meteor Aerospace, and the SaverOne RF sensing transaction.

They’re clearly stacking patents around sensing, autonomy, and resilient communications. Anyone else following the recent IP filings or the overall defense tech story here?

The market punished Embecta after the May earnings report as if the business had permanently broken. But when you step back and look at the facts, the long-term story looks very different.
• The loss of one major customer triggered panic selling. However, management has already explained that they are replacing that lost business with multiple new customers across North America, South America, and Asia, reducing dependence on a single account.
• Many investors continue to focus only on debt. Yet management has repeatedly stated that debt reduction remains a top priority, the company continues generating meaningful cash flow, and refinancing remains available if needed. Debt appears to be a manageable financial issue—not an existential one.
• One of the most overlooked developments is Embecta’s $100 million share repurchase authorization over the next three years. Management stated that repurchases were expected to begin during the second quarter. If buybacks have already started, investors could receive important confirmation in the August 7 earnings report.
• Companies that believe their shares are significantly undervalued often choose to repurchase stock rather than issue more shares. That is a message many investors should not ignore.
• Embecta acquired Owen Mumford, one of the recognized global leaders in autoinjector technology, transforming the company from a legacy diabetes supplier into a broader drug-delivery platform.
• According to the latest industry research, the global autoinjector market is expected to grow from approximately $127 billion in 2026 to more than $300 billion by 2031, making it one of the fastest-growing segments in healthcare.
• Owen Mumford is recognized among leading companies in this industry alongside some of the largest names in medical technology and pharmaceuticals.
• A representative from Dr. Reddy’s publicly highlighted Owen Mumford’s competitive advantages in drug-delivery devices—an important endorsement from one of the world’s leading generic pharmaceutical companies.
• During recent investor conferences, Embecta management stated they have been working with approximately 30 pharmaceutical companies, with around 40% already selecting Embecta as a pen needle supplier. Several launches have already taken place, with approvals expanding into additional markets.
• Embecta also strengthened its leadership by appointing Nimish Muzumdar as Vice President for North America. He previously held senior commercial leadership roles at Sandoz, helping expand one of its major businesses. His extensive experience across North America and strong pharmaceutical industry relationships add meaningful depth to Embecta’s commercial leadership team.
• Management has spent the last several months meeting with major institutional investors through conferences hosted by Bank of America, Jefferies, Goldman Sachs, TD Cowen, and Truist, communicating the company’s long-term strategy.
• Another interesting observation: for more than a month, unusually large closing auction prints have appeared almost every trading session. While nobody knows exactly who is behind those trades, persistent institutional-sized activity at the close suggests that larger market participants continue to be active.
• The August 7 earnings report could be one of the most important updates of the year. Investors will be watching for progress on capital allocation, possible buyback activity, customer expansion, and additional business developments.
The market is still pricing Embecta like a company whose best days are behind it.
Management appears to be building something very different: a diversified medical technology company with global pharmaceutical partnerships, expanding drug-delivery capabilities, experienced leadership, disciplined capital allocation, and exposure to one of the fastest-growing healthcare markets in the world.
https://www.linkedin.com/posts/autoinjectors-market-to-worth-usd-30046-share-7485224840837226496-FRCW/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAF8uyZsBJ4KgRdzHO0a-goDvvWzFA3Mt4oA&utm_campaign=share_via

I’ve been digging into VPR Brands ($VPRB) after their latest 8-K and wanted to get some other opinions on this because the size of the deal relative to the company caught my attention.
On July 10, VPR Brands entered into a Settlement and Patent License Agreement with R.J. Reynolds Vapor Company related to VPRB’s U.S. Patent No. 8,205,622.
According to the 8-K, the deal includes $14.9 million in consideration and resolves the litigation between the two companies.
In return, R.J. Reynolds and its affiliates receive a non-exclusive, worldwide, fully paid-up, perpetual and irrevocable license covering defined products under the patent. Importantly, the agreement says there is no right to sublicense.

What I find interesting is what this potentially says about the underlying patent.
R.J. Reynolds is obviously a major player in the industry, and they chose to settle and secure a permanent license rather than continue fighting the litigation. That doesn’t automatically prove the patent is valid or that VPRB will win against anyone else — the agreement specifically contains no admission of infringement, validity or liability — but a $14.9M settlement/license agreement seems significant for a company the size of VPRB.
The bigger question to me is whether this has implications beyond the RJR case.

If the patent potentially covers products being sold by other major companies, does the RJR agreement strengthen VPRB’s position in pursuing additional licensing agreements or settlements? Or is this more likely to be viewed as a one-time resolution specific to RJR?
I’m also curious how people are valuing the $14.9M payment itself relative to VPRB’s current size and what the company’s balance sheet could look like once the transaction is reflected in its financials.

I have a position in $VPRB, so obviously do your own DD. I’m interested in hearing the bear case too, especially from anyone familiar with patent litigation and licensing.

https://www.stocktitan.net/sec-filings/VPRB/8-k-vpr-brands-lp-reports-material-event-9aa87dfffa66.html

So, yes, it's an OTC stock with individuals in management with questionable reputations and there's something about one of the lead scientists propagating wild alien conspiracy theories, but...

They are moving forward with testing on their Texatron Fusion Engine, which is from what I understand an on-site deployable Fusion based generator.

I have no idea what the science is behind the technology and I'm still not 100% sure this isn't a massive rug pull, but... I'm feeling a run up to testing and I imagine if it goes well the returns could be insane.

Obviously not financial advice, just sharing my degenerate gambling.

Hello everyone, hope you’re all winning here.

I didn’t mean to post so soon but you all still have time to get in before my next post when we are around .50 cents in a couple months.

I made my last post about this American fusion (AMFN) company when we are at .04 cents a few months ago. We are currently at .12 cents but I need to give an update and that’s the manufacturing process is coming very soon.

Right now from today’s press release they’re having 5 physicists observing and validating the Texatrons. You need to understand why this megacorporation spawning from the OTC will be a multi trillion dollar company which will be revealed soon.

They are going to be manufacturing up to 1 GW Texatron energy generators which will power up to 1,000,000 homes. The one who controls the energy, controls the power to the world.
This will be on every carrier, submarine, country, A.I data centers, including Nvidia, Amazon, meta, Microsoft, google and so much more.

Not going to lie this is the easiest money I made in OTC. You can see it, believe it or not. But I know this is real, and dr.Bradenburn has been so busy building this that he has not been able to talk to us shareholders for a while. They will show the world as they are prepping a presentation for the nay sayers but that’s why I’m here telling you newbies who are learning about this now. They will have the real demonstration next month. It’s a good time to do DD and check us out on Stocktwits AMFN.

This world is going to unite through this alien reverse engineered tech that in which all of you will think it’s a scam until it’s not. The point of OTC stocks are to get in before they become a real non-speculative company and this company is merging from speculative to realistic.

This company will be worth dollars very soon, and since I have changed some of your lives already. A huge rush of investors are soon going to be benefiting from AMFN.

Good luck and one love ✌️